Table 2.
Univariate and multivariate analyses for BCSS and OS after PSM.
| Characteristic | BCSS |
OS |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Year of diagnosis | ||||||||
| 2004–2010 | 1 | 1 | 1 | 1 | ||||
| 2011–2015 | 0.913 (0.391–2.133) | 0.833 | 1.085 (0.292–4.036) | 0.903 | 0.624 (0.348–1.119) | 0.113 | 0.658 (0.284–1.523) | 0.328 |
| Age at diagnosis (year) | ||||||||
| < 60 | 1 | 1 | 1 | 1 | ||||
| ≥ 60 | 1.215 (0.622–2.375) | 0.568 | 1.229 (0.609–2.479) | 0.564 | 1.497 (0.999–2.243) | 0.050 | 1.301 (0.853–1.983) | 0.222 |
| ER | ||||||||
| Negative | 1 | 1 | 1 | 1 | ||||
| Positive | 0.431 (0.211–0.883) | 0.021 | 0.467 (0.177–1.236) | 0.125 | 0.813 (0.539–1.225) | 0.322 | 0.604 (0.336–1.086) | 0.092 |
| Unknown | 0.613 (0.182–2.063) | 0.429 | 2.454 (0.072–83.3) | 0.618 | 0.749 (0.353–1.592) | 0.453 | 0.29 (0.077–1.088) | 0.067 |
| PR | ||||||||
| Negative | 1 | 1 | 1 | 1 | ||||
| Positive | 0.48 (0.222–1.038) | 0.062 | 0.793 (0.285–2.209) | 0.658 | 0.909 (0.595–1.389) | 0.660 | 1.28 (0.705–2.326) | 0.418 |
| Unknown | 0.544 (0.163–1.813) | 0.321 | 0.309 (0.009–10.316) | 0.511 | 0.97 (0.517–1.819) | 0.924 | 1.967 (0.665–5.813) | 0.221 |
| HER2 | ||||||||
| Negative | 1 | 1 | 1 | 1 | ||||
| Positive | 0.299 (0.038–2.361) | 0.252 | 0.245 (0.03–1.998) | 0.189 | 0.278 (0.065–1.194) | 0.085 | 0.28 (0.065–1.218) | 0.090 |
| Unknown | 0.849 (0.379–1.902) | 0.691 | 0.798 (0.229–2.789) | 0.724 | 1.1 (0.648–1.869) | 0.723 | 0.805 (0.379–1.713) | 0.574 |
| Grade | ||||||||
| I-II | 1 | 1 | 1 | 1 | ||||
| III-IV | 1.289 (0.282–5.895) | 0.744 | 0.784 (0.154–4.005) | 0.770 | 0.84 (0.338–2.085) | 0.707 | 0.884 (0.337–2.324) | 0.803 |
| Unknown | 0.779 (0.183–3.308) | 0.735 | 0.558 (0.12–2.598) | 0.457 | 0.791 (0.344–1.819) | 0.581 | 0.891 (0.371–2.139) | 0.796 |
| Lymph node | ||||||||
| N1 | 1 | 1 | 1 | 1 | ||||
| N2 | 2.994 (1.246–7.195) | 0.014 | 3.192 (1.263–8.063) | 0.014 | 2.12 (1.327–3.388) | 0.002 | 2.204 (1.352–3.591) | 0.002 |
| N3 | 4.321 (1.941–9.62) | 0.000 | 6.249 (2.56–15.254) | <0.001 | 1.912 (1.185–3.084) | 0.008 | 2.125 (1.261–3.579) | 0.005 |
| RNE | ||||||||
| < 10 | 1 | 1 | 1 | 1 | ||||
| ≥ 10 | 1.044 (0.519–2.098) | 0.904 | 0.557 (0.255–1.216) | 0.142 | 1.158 (0.755–1.776) | 0.503 | 0.995 (0.627–1.579) | 0.984 |
| Chemotherapy | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.901 (0.393–2.065) | 0.806 | 0.739 (0.294–1.856) | 0.520 | 0.45 (0.297–0.684) | <0.001 | 0.379 (0.237–0.604) | <0.001 |
| Local treatment | ||||||||
| Mastectomy + ALND | 1 | 1 | 1 | 1 | ||||
| ALND +radiotherapy | 0.588 (0.299–1.158) | 0.125 | 0.591 (0.297–1.174) | 0.133 | 0.669 (0.45–0.994) | 0.047 | 0.622 (0.414–0.932) | 0.021 |
Abbreviations: ALND, axillary lymph node dissection; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; PR, progesterone receptors; PSM, propensity score matching; RNE, regional lymph node examined.